BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+3.83%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.15B
AUM Growth
+$6.15B
(-6.1%)
Cap. Flow
-$279M
Cap. Flow
% of AUM
-4.53%
Top 10 Holdings %
Top 10 Hldgs %
39.96%
Holding
178
New
9
Increased
65
Reduced
60
Closed
12
Top Buys
| 1 |
Stryker
SYK
|
$32.9M |
| 2 |
Biohaven
BHVN
|
$30.9M |
| 3 |
UnitedHealth
UNH
|
$29M |
| 4 |
Insulet
PODD
|
$28.6M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$26.5M |
Top Sells
| 1 |
Insmed
INSM
|
$75M |
| 2 |
Intuitive Surgical
ISRG
|
$63.3M |
| 3 |
argenx
ARGX
|
$51.2M |
| 4 |
Boston Scientific
BSX
|
$44.6M |
| 5 |
Humana
HUM
|
$40M |
Sector Composition
| 1 | Healthcare | 99.91% |
| 2 | Industrials | 0.05% |
| 3 | Communication Services | 0.02% |
| 4 | Technology | 0.02% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$6.8B
| $394M | 6.4% | 8,260,434 -39,080 | -0.5% | -$1.86M |
|
|
2
argenx
ARGX
$43.6B
| $298M | 4.83% | 691,874 -119,142 | -15% | -$51.2M |
|
3
Vertex Pharmaceuticals
VRTX
$100B
| $278M | 4.52% | 593,461 -75,289 | -11% | -$35.3M |
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $261M | 4.25% | 1,898,640 -157,234 | -8% | -$21.6M |
|
|
5
Intuitive Surgical
ISRG
$170B
| $240M | 3.9% | 539,904 -142,282 | -21% | -$63.3M |
|
6
Alnylam Pharmaceuticals
ALNY
$58.5B
| $224M | 3.63% | 919,834 +1,550 | +0.2% | +$377K |
|
|
7
Boston Scientific
BSX
$156B
| $198M | 3.22% | 2,569,588 -579,088 | -18% | -$44.6M |
|
8
Revolution Medicines
RVMD
$7.1B
| $195M | 3.17% | 5,029,100 -44,500 | -0.9% | -$1.73M |
|
|
9
Stryker
SYK
$150B
| $186M | 3.02% | 545,934 +96,594 | +21% | +$32.9M |
|
10
Moderna
MRNA
$9.37B
| $186M | 3.02% | 1,563,735 -147,354 | -9% | -$17.5M |
|
|
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $169M | 2.75% | 2,471,285 -348,197 | -12% | -$23.8M |
|
12
Agios Pharmaceuticals
AGIO
$2.19B
| $167M | 2.72% | 3,879,548 -126,452 | -3% | -$5.45M |
|
13
Abbott
ABT
$231B
| $167M | 2.71% | 1,606,153 +171,970 | +12% | +$17.9M |
|
14
DexCom
DXCM
$29.5B
| $144M | 2.34% | 1,268,687 +47,490 | +4% | +$5.38M |
|
15
Incyte
INCY
$16.5B
| $131M | 2.12% | 2,153,504 +116 | +0% | +$7.03K |
|
16
Edwards Lifesciences
EW
$47.8B
| $116M | 1.89% | 1,260,461 +157,325 | +14% | +$14.5M |
|
17
Celldex Therapeutics
CLDX
$1.47B
| $110M | 1.79% | 2,971,615 +175,000 | +6% | +$6.48M |
|
|
18
UnitedHealth
UNH
$281B
| $105M | 1.7% | 205,675 +56,956 | +38% | +$29M |
|
|
19
Insulet
PODD
$23.9B
| $87.9M | 1.43% | 435,420 +141,592 | +48% | +$28.6M |
|
20
Becton Dickinson
BDX
$55.3B
| $81.2M | 1.32% | 347,333 -68,367 | -16% | -$16M |
|
21
Medtronic
MDT
$119B
| $78.8M | 1.28% | 1,001,747 -5,253 | -0.5% | -$413K |
|
|
22
Biohaven
BHVN
$1.63B
| $70.8M | 1.15% | 2,040,853 +890,853 | +77% | +$30.9M |
|
|
23
Insmed
INSM
$28.8B
| $68.5M | 1.11% | 1,021,700 -1,120,143 | -52% | -$75M |
|
24
Arvinas
ARVN
$568M
| $63.6M | 1.03% | 2,390,800 | – | – |
|
25
Tandem Diabetes Care
TNDM
$845M
| $62.2M | 1.01% | 1,543,267 -488,621 | -24% | -$19.7M |
|